MAPT and Alzheimer disease: There are several GSK-3β inhibitors have been found to halt AD-mediated pathological events such as tau phosphorylation, Aβ formation, and cognitive and memory impairment [95,96,97], suggesting that GSK-3β inhibitors are the future molecules to treat AD.